medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-8-41-47medalphabet-3692Research ArticleСтатьиВлияние противоопухолевой терапии на репродуктивную систему, возможности сохранения женской фертильностиThe effect of antitumor therapy on the reproductive system, the possibility of preserving female fertilityhttps://orcid.org/0000-0001-8124-109XКарселадзеН. Д.KarseladzeN. D.

Карселадзе Наталья Джимшеровна, к.м.н., врач-терапевт,

Московская область.

Karseladze Natalia D., PhD Med, general practitioner, 

Moscow region.

karseladze@yandex.ruhttps://orcid.org/0000-0002-4293-3285ОрловаН. В.OrlovaN. V.

Орлова Наталья Васильевна, д.м.н., проф., проф. кафедры факультетской терапии педиатрического факультета,

Москва.

Orlova Natalia V., DM Sci (habil.), professor at Dept of faculty therapy,

Moscow.

vrach315@yandex.ruhttps://orcid.org/0000-0001-8375-4569ИльенкоЛ. И.IlyenkoL. I.

Ильенко Лидия Ивановна, д.м.н., проф., декан педиатрического факультета, зав. кафедрой госпитальной педиатрии № 2 педиатрического факультета,

Москва.

Ilyenko Lydia I., DM Sci (habil.), professor, Dean of the Faculty of Pediatrics, head of the Dept of Hospital Pediatrics No. 2 of the Faculty of Pediatrics,

Moscow.

https://orcid.org/0000-0002-7833-935XТигановаО. А.TiganovaO. A.

Тиганова Ольга Александровна, к.м.н., доцент кафедры госпитальной педиатрии педиатрического факультета; врач детский онколог-гематолог,

Москва.

Tiganova Olga A., PhD Med, associate professor at Dept of Hospital Pediatrics of Faculty of Pediatrics; pediatric oncologist-hematologist,

Moscow.

svudy@yandex.ruhttps://orcid.org/0000-0002-8594-6406ДанелянС. Ж.DanelyanS. Zh.

Данелян Соня Жоровна, к.м.н., заместитель главного врача по акушерско-гинекологической помощи,

Москва.

Danelyan Sonya Zh., PhD Med, Deputy Chief Physician for Obstetric and Gynecological Care,

Moscow.

ХугаеваЗ. К.KhugaevaZ. K.

Хугаева Залина Константиновна, к.м.н., врач акушер-гинеколог, онколог,

Москва.

Khugaeva Zalina K., PhD Med, obstetrician-gynecologist, oncologist, Medical Clinic,

Moscow.

zalina-khugaeva@mail.ruМедицинский центр аэропорта Московского авиационного узлаРоссияMoscow Aviation Hub Airport Medical CenterRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава РоссииРоссияPirogov Russian National Research Medical UniversityRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России; ГБУЗ «Морозовская детская городская клиническая больница Департамента здравоохранения города Москвы»РоссияPirogov Russian National Research Medical University; Morozovskaya Children’s City Clinical Hospital of the Moscow Health DeptRussian FederationГБУЗ «Московский многопрофильный клинический центр „Коммунарка“ Департамента здравоохранения города Москвы»РоссияMoscow Multidisciplinary Clinical Center «Kommunarka» of the Moscow Health DeptRussian FederationООО «Клиника «Национальное агентство клинической фармакологии и фармации (НАКФФ)»РоссияNational Agency of Clinical Pharmacology and Pharmacy (NAKFF)Russian Federation20241105202408Современная гинекология (1)4147Copyright © Карселадзе Н.Д., Орлова Н.В., Ильенко Л.И., Тиганова О.А., Данелян С.Ж., Хугаева З.К., 20242024Карселадзе Н.Д., Орлова Н.В., Ильенко Л.И., Тиганова О.А., Данелян С.Ж., Хугаева З.К.Karseladze N.D., Orlova N.V., Ilyenko L.I., Tiganova O.A., Danelyan S.Z., Khugaeva Z.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3692

Влияние злокачественных новообразований и методов их лечения на репродуктивную функцию женщин является одной из значимых проблем онкогинекологии. Механизмы потери фолликулов яичников, вызванной химиотерапией, имеют свои особенности в зависимости от характеристик цитотоксического агента и действуют по-разному на различные популяции клеток яичника. Рассмотрено токсическое действие на фертильность основных групп противоопухолевых препаратов. Нарушение репродуктивной функции имеет негативные последствия для физического и психического здоровья женщины. Применение методов, снижающих воздействие цитотоксических агентов на яичник, позволяет предотвратить преждевременную недостаточность яичников, приводящую к бесплодию. В статье рассмотрены современные методы сохранения фертильности с использованием вспомогательных репродуктивных технологий. Все онкологические больные репродуктивного возраста должны получать полное консультирование по вопросам онкофертильности как можно раньше, в процессе планирования лечения, независимо от типа и стадии заболевания.

The influence of malignant neoplasms and their treatment methods on the reproductive function of women is one of the significant problems of oncogynecology. The mechanisms of ovarian follicle loss caused by chemotherapy have their own characteristics depending on the characteristics of the cytotoxic agent and act differently on different populations of ovarian cells. The toxic effect on fertility of the main groups of antitumor drugs is considered. Reproductive dysfunction has negative consequences for a woman’s physical and mental health. The use of methods that reduce the effect of cytotoxic agents on the ovary helps to prevent premature ovarian insufficiency, leading to infertility. The article discusses modern methods of fertility preservation using assisted reproductive technologies. All cancer patients of reproductive age should receive full oncofertility counseling as early as possible, during the treatment planning process, regardless of the type and stage of the disease.

злокачественные новообразованияхимиотерапиягонадотоксичностьфертильностьвспомогательные репродуктивные технологииmalignant neoplasmschemotherapygonadotoxicityfertilityassisted reproductive technologiesReferencesStearns V, Schneider B, Henry NL, Hayes DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat. Rev. Cancer. 2006; 6: 886–893.Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat. Rev. Cancer. 2006; 6: 886–893.Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical guidelines. Cancer. Manag. Res. 2014 Mar 4; 6: 105–17. DOI: 10.2147/CMAR.S32380Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical guidelines. Cancer. Manag. Res. 2014 Mar 4; 6: 105–17. DOI: 10.2147/CMAR.S32380Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum. Reprod. Update. 2001 Nov-Dec; 7 (6): 535–43. DOI: 10.1093/humupd/7.6.535.Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum. Reprod. Update. 2001 Nov-Dec; 7 (6): 535–43. DOI: 10.1093/humupd/7.6.535.Anderson RA, Mitchell RT, Kelsey TW, Spears N, Telfer EE, Wallace WH. Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults. Lancet Diabetes Endocrinol. 2015 Jul; 3 (7): 556–67. DOI: 10.1016/S2213–8587(15)00039-XAnderson RA, Mitchell RT, Kelsey TW, Spears N, Telfer EE, Wallace WH. Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults. Lancet Diabetes Endocrinol. 2015 Jul; 3 (7): 556–67. DOI: 10.1016/S2213–8587(15)00039-XSpears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson RA, Klinger FG. Ovarian damage from chemotherapy and current approaches to its protection. Hum. Reprod. Update. 2019 Nov 5; 25 (6): 673–693. DOI: 10.1093/humupd/dmz027Spears N, Lopes F, Stefansdottir A, Rossi V, De Felici M, Anderson RA, Klinger FG. Ovarian damage from chemotherapy and current approaches to its protection. Hum. Reprod. Update. 2019 Nov 5; 25 (6): 673–693. DOI: 10.1093/humupd/dmz027Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016 Oct; 12 (20): 2333–44. DOI: 10.2217/fon‑2016–0176Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016 Oct; 12 (20): 2333–44. DOI: 10.2217/fon‑2016–0176Caretto M, Simoncini T. The need to reduce gonadotoxicity! fertility reserve after chemotherapy for gynaecological cancer. Gynecol. Endocrinol. 2021 Jun; 37 (6): 481–482. DOI: 10.1080/09513590.2021.1929153Caretto M, Simoncini T. The need to reduce gonadotoxicity! fertility reserve after chemotherapy for gynaecological cancer. Gynecol. Endocrinol. 2021 Jun; 37 (6): 481–482. DOI: 10.1080/09513590.2021.1929153Chow EJ, Stratton KL, Leisenring WM, Oeffinger KC, Sklar CA, Donaldson SS et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2016 May; 17 (5): 567–76. DOI: 10.1016/S1470–2045(16)00086–3Chow EJ, Stratton KL, Leisenring WM, Oeffinger KC, Sklar CA, Donaldson SS et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2016 May; 17 (5): 567–76. DOI: 10.1016/S1470–2045(16)00086–3Yuksel A, Bildik G, Senbabaoglu F, Akin N, Arvas M, Unal F. et al. The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells. Hum Reprod. 2015 Dec; 30 (12): 2926–35. DOI: 10.1093/humrep/dev256Yuksel A, Bildik G, Senbabaoglu F, Akin N, Arvas M, Unal F. et al. The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells. Hum Reprod. 2015 Dec; 30 (12): 2926–35. DOI: 10.1093/humrep/dev256Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C, Mattei M et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med. 2009 Oct; 15 (10): 1179–85. DOI: 10.1038/nm.2033Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger FG, Di Bartolomeo C, Mattei M et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med. 2009 Oct; 15 (10): 1179–85. DOI: 10.1038/nm.2033Ben-Aharon I, Bar-Joseph H, Tzarfaty G, Kuchinsky L, Rizel S, Stemmer SM, Shalgi R. Doxorubicin-induced ovarian toxicity. Reprod. Biol. Endocrinol. 2010 Mar 4; 8: 20. DOI: 10.1186/1477–7827–8–20Ben-Aharon I, Bar-Joseph H, Tzarfaty G, Kuchinsky L, Rizel S, Stemmer SM, Shalgi R. Doxorubicin-induced ovarian toxicity. Reprod. Biol. Endocrinol. 2010 Mar 4; 8: 20. DOI: 10.1186/1477–7827–8–20Wu C, Wu T, Chen D, Wei S, Tang W, Xue L et al. The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: A review of current evidence. Front Endocrinol (Lausanne). 2022 Nov 24; 13: 1025018. DOI: 10.3389/fendo.2022.1025018Wu C, Wu T, Chen D, Wei S, Tang W, Xue L et al. The effects and mechanism of taxanes on chemotherapy-associated ovarian damage: A review of current evidence. Front Endocrinol (Lausanne). 2022 Nov 24; 13: 1025018. DOI: 10.3389/fendo.2022.1025018Jasirwan S.F. Gonadotoxic Effect of Combined Chemotherapy on Anti Müllerian Hormone (AMH) Level in non-Gynecologic Cancer Patients in Reproductive Age. Indones J. Obstet and Gynecol|. 2010 July 34; 3: 119–124. DOI: https://inajog.com/index.php/journal/article/view/253Jasirwan S.F. Gonadotoxic Effect of Combined Chemotherapy on Anti Müllerian Hormone (AMH) Level in non-Gynecologic Cancer Patients in Reproductive Age. Indones J. Obstet and Gynecol|. 2010 July 34; 3: 119–124. DOI: https://inajog.com/index.php/journal/article/view/253Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemotherapeutic agents damage the ovary? Hum. Reprod. Update. 2012 Sep-Oct; 18 (5): 525–35. DOI: 10.1093/humupd/dms022Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemotherapeutic agents damage the ovary? Hum. Reprod. Update. 2012 Sep-Oct; 18 (5): 525–35. DOI: 10.1093/humupd/dms022Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA. et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016 Jan 4; 14: 1. DOI: 10.1186/s12916–015–0545–7Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA. et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016 Jan 4; 14: 1. DOI: 10.1186/s12916–015–0545–7Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K. et al. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol. 2006 Jun 20; 24 (18): 2917–31. DOI: 10.1200/JCO.2006.06.5888Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K. et al. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol. 2006 Jun 20; 24 (18): 2917–31. DOI: 10.1200/JCO.2006.06.5888ESHRE Guideline Group on Female Fertility Preservation; Anderson RA, Amant F, Braat D, D’Angelo A, Chuva de Sousa Lopes SM, Demeestere I. et al. ESHRE guideline: female fertility preservation. Hum. Reprod. Open. 2020 Nov 14; 2020 (4): hoaa052. DOI: 10.1093/hropen/hoaa052ESHRE Guideline Group on Female Fertility Preservation; Anderson RA, Amant F, Braat D, D’Angelo A, Chuva de Sousa Lopes SM, Demeestere I. et al. ESHRE guideline: female fertility preservation. Hum. Reprod. Open. 2020 Nov 14; 2020 (4): hoaa052. DOI: 10.1093/hropen/hoaa052Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE. et al. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil. Steril. 2013 Feb; 99 (2): 477–83. DOI: 10.1016/j.fertnstert.2012.09.039Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE. et al. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil. Steril. 2013 Feb; 99 (2): 477–83. DOI: 10.1016/j.fertnstert.2012.09.039Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M. et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J. Clin. Oncol. 2018 Jul 1; 36 (19): 1981–1990. DOI: 10.1200/JCO.2018.78.0858Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M. et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J. Clin. Oncol. 2018 Jul 1; 36 (19): 1981–1990. DOI: 10.1200/JCO.2018.78.0858Cobo A, García-Velasco J, Domingo J, Pellicer A, Remohí J. Elective and Onco-fertility preservation: factors related to IVF outcomes. Hum. Reprod. 2018 Dec 1; 33 (12): 2222–2231. DOI: 10.1093/humrep/dey321Cobo A, García-Velasco J, Domingo J, Pellicer A, Remohí J. Elective and Onco-fertility preservation: factors related to IVF outcomes. Hum. Reprod. 2018 Dec 1; 33 (12): 2222–2231. DOI: 10.1093/humrep/dey321Rodriguez-Wallberg KA, Waterstone M, Anastácio A. Ice age: Cryopreservation in assisted reproduction – An update. Reprod. Biol. 2019 Jun; 19 (2): 119–126. DOI: 10.1016/j.repbio.2019.04.002Rodriguez-Wallberg KA, Waterstone M, Anastácio A. Ice age: Cryopreservation in assisted reproduction – An update. Reprod. Biol. 2019 Jun; 19 (2): 119–126. DOI: 10.1016/j.repbio.2019.04.002Masciangelo R, Bosisio C, Donnez J, Amorim CA, Dolmans MM. Safety of ovarian tissue transplantation in patients with borderline ovarian tumors. Hum. Reprod. 2018 Feb 1; 33 (2): 212–219. DOI: 10.1093/humrep/dex352Masciangelo R, Bosisio C, Donnez J, Amorim CA, Dolmans MM. Safety of ovarian tissue transplantation in patients with borderline ovarian tumors. Hum. Reprod. 2018 Feb 1; 33 (2): 212–219. DOI: 10.1093/humrep/dex352Hartnett KP, Mertens AC, Kramer MR, Lash TL, Spencer JB, Ward KC, Howards PP. Pregnancy after cancer: Does timing of conception affect infant health? Cancer. 2018 Nov 15; 124 (22): 4401–4407. DOI: 10.1002/cncr.31732. Epub 2018 Nov 7Hartnett KP, Mertens AC, Kramer MR, Lash TL, Spencer JB, Ward KC, Howards PP. Pregnancy after cancer: Does timing of conception affect infant health? Cancer. 2018 Nov 15; 124 (22): 4401–4407. DOI: 10.1002/cncr.31732. Epub 2018 Nov 7Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D. et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015 Dec; 26 (12): 2408–19. DOI: 10.1093/annonc/mdv374Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D. et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015 Dec; 26 (12): 2408–19. DOI: 10.1093/annonc/mdv374Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P et al. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. J. Clin. Oncol. 2016 Aug 1; 34 (22): 2568–74. DOI: 10.1200/JCO.2015.65.8864Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P et al. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. J. Clin. Oncol. 2016 Aug 1; 34 (22): 2568–74. DOI: 10.1200/JCO.2015.65.8864Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 2018 Jul 1; 36 (19): 1994–2001. DOI: 10.1200/JCO.2018.78.1914. Epub 2018 Apr 5. PMID: 29620997Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 2018 Jul 1; 36 (19): 1994–2001. DOI: 10.1200/JCO.2018.78.1914. Epub 2018 Apr 5. PMID: 29620997Ahn RW, Barrett SL, Raja MR, Jozefik JK, Spaho L, Chen H et al. Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. PLoS One. 2013; 8 (3): e58491. DOI: 10.1371/journal.pone.0058491Ahn RW, Barrett SL, Raja MR, Jozefik JK, Spaho L, Chen H et al. Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. PLoS One. 2013; 8 (3): e58491. DOI: 10.1371/journal.pone.0058491Roness H, Kashi O, Meirow D. Prevention of chemotherapy-induced ovarian damage. Fertil Steril. 2016 Jan; 105 (1): 20–9. DOI: 10.1016/j.fertnstert.2015.11.043Roness H, Kashi O, Meirow D. Prevention of chemotherapy-induced ovarian damage. Fertil Steril. 2016 Jan; 105 (1): 20–9. DOI: 10.1016/j.fertnstert.2015.11.043Köhler TS, Kondapalli LA, Shah A, Chan S, Woodruff TK, Brannigan RE. Results from the survey for preservation of adolescent reproduction (SPARE) study: gender disparity in delivery of fertility preservation message to adolescents with cancer. J. Assis.t Reprod. Genet. 2011 Mar; 28 (3): 269–77. DOI: 10.1007/s10815–010–9504–6Köhler TS, Kondapalli LA, Shah A, Chan S, Woodruff TK, Brannigan RE. Results from the survey for preservation of adolescent reproduction (SPARE) study: gender disparity in delivery of fertility preservation message to adolescents with cancer. J. Assis.t Reprod. Genet. 2011 Mar; 28 (3): 269–77. DOI: 10.1007/s10815–010–9504–6Melan K, Amant F, Veronique-Baudin J, Joachim C, Janky E. Fertility preservation healthcare circuit and networks in cancer patients worldwide: what are the issues? BMC Cancer. 2018 Feb 17; 18 (1): 192. DOI: 10.1186/s12885–018–4046-xMelan K, Amant F, Veronique-Baudin J, Joachim C, Janky E. Fertility preservation healthcare circuit and networks in cancer patients worldwide: what are the issues? BMC Cancer. 2018 Feb 17; 18 (1): 192. DOI: 10.1186/s12885–018–4046-xПорядок использования вспомогательных репродуктивных технологий, противопоказания и ограничения к их применению. Приложение N1 к приказу Министерства здравоохранения Российской Федерации от 31 июля 2020 г. N803н. Часть 3, пункт 31–34. https://www.garant.ru/products/ipo/prime/doc/74676088The procedure for the use of assisted reproductive technologies, contraindications and restrictions to their use. Appendix No. 1 to the order of the Ministry of Health of the Russian Federation dated July 31, 2020 No. 803n. Part 3, paragraph 31–34. https://www.garant.ru/products/ipo/prime/doc/74676088Письмо Министерства здравоохранения РФ от 15 февраля 2019 г. N15–4/И/2–1217 О направлении клинических рекомендаций (протокола лечения) «Вспомогательные репродуктивные технологии и искусственная инсеминация». https://www.garant.ru/products/ipo/prime/doc/72113052Letter of the Ministry of Health of the Russian Federation dated February 15, 2019 No. 15–4/I/2–1217 On the direction of clinical recommendations (treatment protocol) «Assisted reproductive technologies and artificial insemination» https://www.garant.ru/products/ipo/prime/doc/72113052Письмо Минздрава РФ от 05.03.2019 N 15–4/И/2–1913 – О направлении клинических рекомендаций (протокола лечения) «’Женское бесплодие (современные подходы к диагностике и лечению)». https://www.consultant.ru/document/cons_doc_LAW_322996Letter of the Ministry of Health of the Russian Federation dated 05.03.2019 No. 15–4/I/2–1913 – On the direction of clinical recommendations (treatment protocol) «Female infertility (modern approaches to diagnosis and treatment)» https://www.consultant.ru/document/cons_doc_LAW_322996

The authors declare that there are no conflicts of interest present.